Low dosis of alteplase, for ischemic stroke after Enchanted and its determinants, a single center experience
Autor: | Enrico Mazzon, Alexis Rojo, Gabriel Cavada, Paula Muñoz-Venturelli, Verónica V. Olavarría, Juan Almeida, Eloy Mansilla, Alejandro M. Brunser, Pablo M. Lavados |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Male
Therapeutic Thrombolysis medicine.medical_specialty medicine.medical_treatment Neurosciences. Biological psychiatry. Neuropsychiatry Brain Ischemia Terapia Trombolítica Coronary artery disease Accidente Cerebrovascular Fibrinolytic Agents Modified Rankin Scale Internal medicine Acute Stroke Medicine Humans Thrombolytic Therapy Prospective Studies Prospective cohort study Stroke Aged Ischemic Stroke Aged 80 and over Univariate analysis business.industry Leukoaraiosis Thrombolysis Middle Aged medicine.disease Treatment Outcome Neurology Tissue Plasminogen Activator Female Neurology (clinical) business Fibrinolytic agent RC321-571 |
Zdroj: | Arquivos de Neuro-Psiquiatria, Vol 78, Iss 11, Pp 681-686 (2020) Arquivos de Neuro-Psiquiatria v.78 n.11 2020 Arquivos de neuro-psiquiatria Academia Brasileira de Neurologia instacron:ABNEURO Arquivos de Neuro-Psiquiatria, Volume: 78, Issue: 11, Pages: 681-686, Published: 14 DEC 2020 |
ISSN: | 1678-4227 |
Popis: | Background: Low-dose alteplase (LrtPA) has been shown not to be inferior to the standard-dose (SrtPA) with respect to death/disability. Objective: We aim to evaluate the percentage of patients treated with LrtPA at our center after the ENCHANTED trial and the factors associated with the use of this dosage. Methods: Prospective study in consecutive patients with an acute stroke admitted between June 2016 and November 2018. Results: 160 patients were treated with intravenous thrombolysis, 50% female; mean age 65.4±18.5 years. Of these, 48 patients (30%) received LrtPA. In univariate analysis, LrtPA was associated with patient's age (p=0.000), previous modified Rankin scale scores (mRS) (p |
Databáze: | OpenAIRE |
Externí odkaz: |